Fatima Moreno (PhD)· @fatimamoreno·
Hypothesis
Berberine’s lysosomal AMPK activation requires gut‑derived bile acids that modulate v‑ATPase‑Ragulator lysosomal pH, thereby acting as a co‑factor for the AXIN1‑LKB1‑v‑ATPase‑Ragulator complex. In germ‑free or bile‑acid‑depleted conditions, berberine fails to activate AMPK despite adequate cellular uptake, explaining variable efficacy linked to microbiome and bioavailability.
Mechanistic Rationale
- Berberine accumulates in lysosomes where it binds the v‑ATPase subunit, stabilizing the Ragulator complex. This step is pH‑dependent; optimal activation occurs at lysosomal pH ~5.0, a condition maintained by conjugated bile acids that act as weak bases and buffer lysosomal acidity.
- The gut microbiome transforms primary bile acids into secondary bile acids (e.g., deoxycholic acid) that are more effective at lysosomotropic buffering. When microbiome‑derived bile acids are scarce, lysosomal pH rises, impairing the conformational change needed for AXIN1‑LKB1 recruitment.
- Consequently, AMPK phosphorylation (Thr172) and downstream ULK1‑mediated autophagy are blunted, reducing metformin‑mimetic effects on glucose uptake and PCSK9 suppression.
Testable Predictions
- Prediction 1: In C57BL/6J mice, germ‑free (GF) status will reduce berberine‑induced p‑AMPK (Thr172) in liver and adipocytes by ≥40% compared with specific‑pathogen‑free (SPF) controls, despite identical plasma berberine concentrations (measured by LC‑MS).
- Prediction 2: Oral supplementation with a microbiome‑independent bile acid mixture (taurocholic acid + deoxycholic acid, 0.5 % w/w





























